{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:53:04Z","timestamp":1794963184431,"version":"4.9.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Novel antibodies to trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor receptor 3 (FGFR-3) have been recently described in otherwise cryptogenic small fiber neuropathy (SFN) cases. Our goal was to further describe clinical features in such cases and to analyze treatment responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In a retrospective analysis, 40 cases of cryptogenic SFN in a university neuropathy clinic were identified. Of these, TS-HDS and FGFR-3 cases were identified, and clinical features and treatment responses were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In this cohort, 95% were women, and 55% had either TS-HDS or FGFR-3 antibodies (77% of these had TS-HDS). Of the seropositive group, 41% had a nonlength dependent epidermal nerve fiber density on skin punch biopsy (OR = 1.80). In the seropositive group, 82% had neuropathic pain as their primary symptom (OR = 1.73). Also 32% of seropositive patients reported widespread pain (OR = 1.63). 63% of seropositive cases presented acutely (OR = 11.0). In the seropositive group, 23% had an initial erroneous diagnosis (OR = 1.47). Eight seropositive patients improved on intravenous immunoglobulin treatment, with a 42% reduction in pain scores (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02), a 44% reduction in the Utah Neuropathy Score, and improved epidermal nerve fiber density post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TS-HDS and FGFR-3 antibodies may be present in a high proportion of cryptogenic SFN cases with acute onset, nonlength dependent pathology, and primary neuropathic and widespread pain. They are often misdiagnosed as other conditions including fibromyalgia. These cases may be responsive to immune treatment, especially with intravenous immunoglobulin.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000355","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T15:00:09Z","timestamp":1621609209000},"page":"192-199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Clinical Features and Treatment Response in Immune-Mediated Small Fiber Neuropathy with Trisulfated Heparin Disaccharide or Fibroblast Growth Factor Receptor 3 Antibodies"],"prefix":"10.1097","volume":"22","author":[{"given":"Lawrence A.","family":"Zeidman","sequence":"first","affiliation":[{"name":"Division of Neurosciences, Northwest Community Healthcare, Arlington Heights, IL; and"},{"name":"Loyola University Chicago Stritch School of Medicine, Maywood, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Kubicki","sequence":"additional","affiliation":[{"name":"Loyola University Chicago Stritch School of Medicine, Maywood, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/WNL.0b013e3182a8236e","article-title":"Incidence and prevalence of small-fiber neuropathy: a survey in The Netherlands","volume":"81","author":"Peters","year":"2013","journal-title":"Neurology."},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ncl.2020.09.006","article-title":"Advances in the management of small fiber neuropathy","volume":"39","author":"Zeidman","year":"2021","journal-title":"Neurol Clin."},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"1756285617744484","DOI":"10.1177\/1756285617744484","article-title":"IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety","volume":"11","author":"Liu","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mus.26748","article-title":"Cryptogenic small-fiber neuropathies: serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3","volume":"61","author":"Levine","year":"2020","journal-title":"Muscle Nerve."},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/mus.23256","article-title":"Clinical and laboratory features of neuropathies with serum IgM binding to TS-HDS","volume":"45","author":"Pestronk","year":"2012","journal-title":"Muscle Nerve."},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mus.10301","article-title":"Sensory neuropathy with monoclonal igm binding to a trisulfated heparin disaccharide","volume":"27","author":"Pestronk","year":"2003","journal-title":"Muscle Nerve."},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/jnnp-2014-309730","article-title":"Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy","volume":"86","author":"Antoine","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2017.03.011","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"126","author":"Tavee","year":"2017","journal-title":"Respir Med."},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1468-1331.2008.02305.x","article-title":"Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease","volume":"15","author":"Souayah","year":"2008","journal-title":"Eur J Neurol."},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3181a92b52","article-title":"Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy","volume":"9","author":"Iodice","year":"2009","journal-title":"Neurology."},{"key":"R11-20250507","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1529-8027.2008.00180.x","article-title":"The UT Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy","volume":"13","author":"Singleton","year":"2008","journal-title":"J Peripher Nerv Syst."},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1468-1331.2010.03023.x","article-title":"European federation of neurological societies\/peripheral nerve society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European federation of neurological Societies and the peripheral nerve society","volume":"17","author":"Lauria","year":"2010","journal-title":"Eur J Neurol."},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1529-8027.2010.00271.x","article-title":"Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study","volume":"15","author":"Lauria","year":"2010","journal-title":"J Peripher Nerv Syst."},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11910-010-0094-6","article-title":"Utility of skin biopsy to evaluate peripheral neuropathy","volume":"10","author":"Hays","year":"2010","journal-title":"Curr Neurol Neurosci Rep."},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CND.0000000000000236","article-title":"Prevalence of axonal sensory neuropathy with IgM binding to trisulfated heparin disaccharide in patients with fibromyalgia","volume":"20","author":"Malik","year":"2019","journal-title":"J Clin Neuromusc Dis."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/mus.25082","article-title":"Small fiber neuropathy: getting bigger!","volume":"53","author":"Chan","year":"2016","journal-title":"Muscle Nerve."},{"issue":"16 ssuppl","key":"R17-20250507","article-title":"Identification of a novel immune mediated cause for small fiber neuropathy (P4.137)","volume":"88","author":"Levine","year":"2017","journal-title":"Neurology."},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CND.0000000000000221","article-title":"FGFR3 antibodies in neuropathy: what to do with them?","volume":"20","author":"Samara","year":"2018","journal-title":"J Clin Neuromuscul Dis."}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:05:08Z","timestamp":1746651908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000355","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}